La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Y-mAbs Therapeutics Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mike Rossi

Amministratore delegato

US$3.1m

Compenso totale

Percentuale dello stipendio del CEO	3.5%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	3.4yrs
Durata media del Consiglio di amministrazione	6.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mike Rossi rispetto agli utili di Y-mAbs Therapeutics?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$110k	-US$21m

Compensazione vs Mercato: La retribuzione totale di Mike ($USD 3.11M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 2.44M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Mike con le performance aziendali.

AMMINISTRATORE DELEGATO

Mike Rossi (53 yo)

less than a year

Mandato

US$3,110,553

Compensazione

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	Nessun dato
Thomas Gad	Founder	9.3yrs	US$2.45m	0.75% $ 4.2m
Susan Smith	Senior VP & Chief Commercial Officer	2.6yrs	US$887.28k	0.0095% $ 53.1k
Peter Pfreundschuh	CFO & Treasurer	less than a year	Nessun dato	Nessun dato
Joris Wiel Wilms	Senior VP & COO	6.8yrs	Nessun dato	0.013% $ 74.1k
Torben Lund-Hansen	Senior VP & CTO	8.6yrs	Nessun dato	0.12% $ 644.4k
Courtney Dugan	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Vignesh Rajah	Senior VP & Chief Medical Officer	4.2yrs	US$724.92k	0.019% $ 106.0k
Norman D. LaFrance	Chief Development Officer	less than a year	Nessun dato	Nessun dato

3.4yrs

Durata media

54.5yo

Età media

Gestione esperta: Il team dirigenziale di YMAB è considerato esperto (durata media dell'incarico 3.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	Nessun dato
Thomas Gad	Founder	9.3yrs	US$2.45m	0.75% $ 4.2m
James Healy	Independent Chairman of the Board	6.8yrs	US$184.31k	0.063% $ 351.1k
David Gill	Independent Director	6.7yrs	US$180.56k	0.0052% $ 29.1k
Mary Tagliaferri	Director	less than a year	Nessun dato	0% $ 0
Johan Wedell-Wedellsborg	Independent Director	8.9yrs	US$158.06k	0.0052% $ 29.1k
Ashutosh Tyagi	Independent Director	6.8yrs	US$158.06k	0.0052% $ 29.1k
Laura Hamill	Independent Director	4.2yrs	US$168.06k	0.0052% $ 29.1k

6.7yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di YMAB sono considerati esperti (durata media dell'incarico 6.7 anni).

Y-mAbs Therapeutics Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Executive VP notifies of intention to sell stock

Founder recently sold US$396k worth of stock

Recent updates

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Small Cap Comp Value Index

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Executive VP notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Y-mAbs: There's A Ceiling Here Somewhere

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Y-mAbs Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application

Price target decreased to US$12.00

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2022